Prevention of tension type headache with topiramate;Prevencija tenzijske glavobolje topiramatom

Acta Medica Croatica

Volumn 62, Issue 2, 2008, Pages 145-149

  Aleksić Shihabi, Anka ^a   Lojen, Gordana ^a   Vuković, Vlasta ^b  

^a Odjel Neurologije   (Croatia)

^b SESTRE MILOSRDNICE UNIVERSITY HOSPITAL   (Croatia)

Author keywords

Headache; Prevention; Tension type headache; Topiramate

Indexed keywords

TOPIRAMATE;

ARTICLE; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG EFFICACY; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; PREVALENCE; PRIMARY HEADACHE; QUALITY OF LIFE; TENSION HEADACHE; TREATMENT RESPONSE; VISUAL ANALOG SCALE;

ADULT; AGED; AGED, 80 AND OVER; ANTICONVULSANTS; FEMALE; FRUCTOSE; HUMANS; MALE; MIDDLE AGED; PAIN MEASUREMENT; QUALITY OF LIFE; TENSION-TYPE HEADACHE;

EID: 48349101054     PISSN: 13300164     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988; 8(Suppl 7): 1-96.
2. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders: 2nd edition. Cephalalgia 2004; 24 (Suppl 1): 9-160.
3. Puca F, Genco S, Prudenzano MP i sur. Psychiatric comorbidity and psychosodal stress in patients with tension-type headache from headache centers in Italy. The Italian Collaborative Group for the Study of Psychopathological Factors in Primary Headaches. Cephalalgia 1999; 19: 159-64.
4. Schwartz BS, Stewart WF, Simon D, Lipton RB. Epidemiology of tension-type headache. JAMA 1998; 279: 381-3.
5. Demarin V, Vuković V, Lovrenčić-Huzjan A i sur. Evidence based guidelines for treatment of primary headaches. Report of The Croatian Neurovascular Society. Acta Clin Croat 2005; 44: 139-183.
6. Fernandez-de-Las-Penas C, Ge HY, Arendt-Nielsen L, Cuadrado ML, Pareja JA. The local and referred pain from myofascial trigger points in the temporalis musde contributes to pain profile in chronic tension-type headache. Clin J Pain 2007; 23: 786-92.
7. Olesen J, Schoenen J, ur. Tension-type headache. Classification, mechanisms, and treatment. Frontiers in headache research, Vol 3. New York: Raven Press, 1993.
8. Ashina M, Bendtsen L, Jensen R, Olesen J. Nitric oxide-induced headache in patients with chronic tension-type headache. Brain 2000; 123: 1830-7.
9. Ashina M, Simonsen H, Bendtsen L, Jensen R, Olesen J. Glyceril trinitrate may trigger endogenous nitric oxide production in patients with chronic tension-type headache. Cephalalgia 2004; 24: 967-72.
10. Mathew NT, Ashina M. Acute pharmacotherapy of tension-type headaches. U: Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, ur. The headaches, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2006, 971-9.
11. Diener HC, Pfaffenrath V, Pageler L i sur. The fixed combination of acetylsalicylic add, paracetamol, and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-doze, placebo-controlled parallel group study. Cephalalgia 2005; 25: 776-87
12. Tfelt-Hansen P. Acute pharmacotherapy of migraine, tension-type headache, and cluster headache. J Headache Pain 2007; 8: 127-34.
13. White HS. Molecular pharmacology of topiramate: managing seizures and preventing migraine. Headache 2005; 45(Supl 1): 48-56.
14. French JA, Kanner AM, Bautista J i sur. Efficacy and tolerability of the new antiepileptic drugs, I: Treatment of new-onset epilepsy: report of the TTA and QSS Subcommittees of the American Academy of Neurology and the American Epilepsy Society. Epilepsia 2004; 45: 401-9.
15. Wang Y, Zhou D, Wang B i sur. Clinical effects of topiramate against secondarily generalized tonic-donic seizures. Epilepsy Res 2002; 49: 121-30.
16. Diener HC, Tfelt-Hansen P, Dahlof C; MIGR-003 Study Group. Topiramate in migraine prophylaxis-results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004; 251: 943-50.
17. Silberstein SD, Neto W, Schmitt J, Jacobs D; MIGR -001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch Neurol 2004; 61: 490-5.
18. Brandes JL, Saper JR, Diamond M i sur. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291: 965-73.
19. Dodick DW, Silberstein S, Saper J i sur. The impact ot topiramate on health-related quality of life indicators in chronic migraine. Headache 2007; 47: 1398-408.
20. Dahlof C, Loder E, Diamond M, Rupnow M, Papadopoulos G, Mao L. The impact of migraine prevention on daily activities: a longitudinal and responder analysis from three topiramate placebo-controlled clinical trials. Health Qual Life Outcomes 2007; 4: 5: 56.
21. Wenzel RG, Schwarz K, Padiyara RS. Topiramate for migraine prevention. Pharmacotherapy 2006; 26: 375-87.
22. Brandes JL. Practical use of topiramate for migraine prevention. Headache 2005; 45: 66-73.
23. Fontebasso M. Topiramate for migraine prophylaxis. Expert Opin Pharmacother 2007; 8: 2811-23.
24. Lampl C, Marecek S, May A, Bendtsen L. A prospective, open-label, long-term study of the efficacy and telerability of topiramate in the prophylaxis of chronic tension-type headache. Cephalalgia 2006; 26: 1203-8.
25. D'Amico D. Antiepileptic drugs in the prophylaxis of migraine, chronic headache forms and cluster headache: a review of their efficacy and tolerability. Neurol Sci 2007; 28: 188-97.
26. Mathew NT. The prophylactic treatment of chronic daily headache. Headache 2006; 46: 1552-64.
27. Diamond M, Dahlof C, Papadopoulos G, Neto W Wu SC. Topiramate improves health-related quality of life when used to prevent migraine. Headache 2005; 45: 1023-30.
28. Peres MF, Mercante JP, Tanuri FC, Nunes M, Zukerman E. Chronic migraine prevention with topiramate. Headache Pain 2006; 7: 185-7.